Jumping back into the cancer field, GlaxoSmithKline (GSK) has agreed to acquire oncology specialist Tesaro in a deal worth £4 B (US$5.1 B). The move gives GSK access to the latter’s lead candidate, Zejula® (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor for the treatment of various cancers. Despite having exited the oncology space in 2014 by selling its established cancer portfolio to Novartis, GSK is now ready to take on competition from other PARP drugs such as Lynparza® (olaparib) from AstraZeneca and Clovis Oncology’s Rubraca® (rucaparib), as well as the new challenger, Talzenna® (talazoparib), from Pfizer.